251 related articles for article (PubMed ID: 20067769)
1. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Sabisz M; Wesierska-Gadek J; Skladanowski A
Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Cimmino G; Pepe S; Laus G; Chianese M; Prece D; Penitente R; Quesada P
Pharmacol Res; 2007 Jan; 55(1):49-56. PubMed ID: 17127074
[TBL] [Abstract][Full Text] [Related]
3. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.
Wesierska-Gadek J; Schloffer D; Gueorguieva M; Uhl M; Skladanowski A
Cancer Res; 2004 Jul; 64(13):4487-97. PubMed ID: 15231658
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
6. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Sabbatino F; Fusciello C; Somma D; Pacelli R; Poudel R; Pepin D; Leonardi A; Carlomagno C; Della Vittoria Scarpati G; Ferrone S; Pepe S
Cytometry A; 2014 Nov; 85(11):953-61. PubMed ID: 25182801
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
Bowman KJ; White A; Golding BT; Griffin RJ; Curtin NJ
Br J Cancer; 1998 Nov; 78(10):1269-77. PubMed ID: 9823965
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
9. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
[TBL] [Abstract][Full Text] [Related]
11. BubR1 is involved in regulation of DNA damage responses.
Fang Y; Liu T; Wang X; Yang YM; Deng H; Kunicki J; Traganos F; Darzynkiewicz Z; Lu L; Dai W
Oncogene; 2006 Jun; 25(25):3598-605. PubMed ID: 16449973
[TBL] [Abstract][Full Text] [Related]
12. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.
Nabha SM; Mohammad RM; Dandashi MH; Coupaye-Gerard B; Aboukameel A; Pettit GR; Al-Katib AM
Clin Cancer Res; 2002 Aug; 8(8):2735-41. PubMed ID: 12171907
[TBL] [Abstract][Full Text] [Related]
15. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
[TBL] [Abstract][Full Text] [Related]
16. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.
Madison DL; Stauffer D; Lundblad JR
DNA Repair (Amst); 2011 Oct; 10(10):1003-13. PubMed ID: 21840268
[TBL] [Abstract][Full Text] [Related]
17. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
[TBL] [Abstract][Full Text] [Related]
18. Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle.
Maurer M; Komina O; Składanowski A; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):5-15. PubMed ID: 21275261
[TBL] [Abstract][Full Text] [Related]
19. Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Montariello D; Troiano A; Di Girolamo D; Beneke S; Calabrò V; Quesada P
Biochem Pharmacol; 2015 Apr; 94(3):212-9. PubMed ID: 25667043
[TBL] [Abstract][Full Text] [Related]
20. PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Luo Q; Li Y; Deng J; Zhang Z
Chem Biol Interact; 2015 Jan; 226():12-22. PubMed ID: 25499136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]